Bioequivalence of Two Formulations of Levothyroxine Sodium 200 Micrograms (mcg) Under Tablet Form
Status:
Completed
Trial end date:
2019-09-11
Target enrollment:
Participant gender:
Summary
The study was to verify if the test formulation of Levothyroxine sodium presents an
equivalent rate and extension of absorption to the comparator formulation when administered
with the same dosage and under fasting conditions and after baseline correction
concentrations.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, Germany Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany